BSE filing, NSE: BAFNAPH. Summary written from the filing by ALFA Finder's alert engine.
Bafna Pharmaceuticals Ltd: key numbers
- Share price
- ₹451.60
- Market cap
- ₹1,068 Cr
- Revenue (annual)
- ₹150.6 Cr
- Net profit (annual)
- ₹11.10 Cr
- P/E (TTM)
- 137.2×Sector 46.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 9.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bafna Pharmaceuticals Ltd
All →Bafna Pharmaceuticals Other Announcement
Bafna Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals' 31st AGM held on September 11, 2026 approved adoption of audited financials, a director re-appointment, and cost auditor ratification. No specific monetary transaction was transacted.
Bafna Pharmaceuticals Annual Report
Bafna Pharmaceuticals Limited has submitted its Annual Report for the financial year 2025-2026 and announced the date for its 31st Annual General Meeting.
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals Limited will hold its 31st Annual General Meeting on September 11, 2026. The book closure is scheduled from September 05 to September 11, 2026.
Bafna Pharmaceuticals Q1 FY27 Results: Net Profit ₹0.1 Cr, Down 97.1% YoY
Bafna Pharmaceuticals Ltd reported revenue from operations of ₹26.6 Cr (-23.1% YoY) and net profit of ₹0.1 Cr (-97.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.1 Cr · -97.1% YoY
Bafna Pharmaceuticals Board Meeting Date
Bafna Pharmaceuticals has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.